OBJECTIVE: To report the occurrence of severe @entity3043 associated with low-dose @entity1499 ( @entity1500 ) therapy for @entity309 . CASE SUMMARY: Two @entity1 developed severe @entity3043 after 10 days (cumulative dose 15 mg) and 23 months (cumulative dose 1030 mg), respectively, of low-dose @entity1500 therapy for @entity309 . Both @entity1 had @entity8 . One died and the other recovered completely. DISCUSSION: @entity3043 is a rare adverse effect of low-dose oral @entity1500 therapy. The exact mechanism for development of @entity3043 is unknown, although it is likely that several factors play a role. The most important risk factor for @entity1500 @entity137 is @entity8 . This adverse effect may occur at any time during @entity1500 therapy. CONCLUSIONS: Severe @entity3043 associated with low-dose @entity1500 therapy for @entity309 is a potentially serious complication that may occur at any time during therapy. This adverse effect is more likely to occur in @entity1 with @entity8 .

Severe @entity3043 associated with low-dose XXXX therapy for @entity309 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'impaired renal function'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity3043 :: ('MESH:D010198', 'Disease') :: ['Pancytopenia', 'pancytopenia'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']
@entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']
